[1]苏婷,张盼晓,王志禄.前蛋白转化酶枯草溶菌素9抑制剂: 阿利库单抗的研究进展[J].心血管病学进展,2016,(1):78-81.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.020]
　SU Ting,ZHANG Panxiao,WANG Zhilu.Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: Research Advances in Alirocumab[J].Advances in Cardiovascular Diseases,2016,(1):78-81.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.020]
点击复制

前蛋白转化酶枯草溶菌素9抑制剂: 阿利库单抗的研究进展()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2016年1期
页码:
78-81
栏目:
综述
出版日期:
2016-02-20

文章信息/Info

Title:
Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: Research Advances in Alirocumab
作者:
苏婷; 张盼晓; 王志禄
兰州大学第一医院,甘肃 兰州730000
Author(s):
SU Ting;  ZHANG Panxiao;  WANG Zhilu
The First Clinical Medical College of Lanzhou University, Lanzhou 730000,Gansu, China
关键词:
阿利库单抗;  前蛋白转化酶枯草溶菌素9;  低密度脂蛋白胆固醇
Keywords:
Alirocumab;  Proprotein convertase subtilisin kexin type 9;  Low-density lipoprotein cholesterol
分类号:
R972+6
DOI:
10.16806/j.cnki.issn.1004-3934.2016.01.020
文献标志码:
A
摘要:
他汀类药物被认为是降低低密度脂蛋白胆固醇最有效的药物,从而降低心脑血管疾病的发病率和病死率。然而,他汀类药物不耐受是限制其使用的一个重要原因,尤其是大剂量时。随着前蛋白转化酶枯草溶菌素9的发现,血脂异常的调节有了一个新的方向。阿利库单抗是一种靶向作用于枯草溶菌素9的人源性单克隆抗体,在一系列研究中显示出了良好的前景。现就阿利库单抗的最新研究进展进行综述。
Abstract:
Statins are the most effective medications presently available to reduce low-density lipoprotein cholesterol and decrease the mobility and mortality of cardiovascular and cerebrovascular disease. However, statin intolerance has been a major limitation in the use of statins, especially at higher doses. Following the discovery of proprotein convertase subtilisin kexin type 9(PCSK9), a new direction has been provided to regulate cholesterol metabolism. Alirocumab, which trade name is Praluent(SAR236553/REGN727),is a fully human monoclonal antibody to PCSK9 and has shown good results in a serious of research. The clinical trials research of alirocumab are reviewed in this paper.

参考文献/References:

[1] Bays HE, Jones PH, Brown WV, et al. National Lipid Association Annual Summary of Clinical Lipidology 2015[J]. J Clin Lipidol,2014,8(6 Suppl):S1-S36.
[2] Fulcher J, O'Connell R, Voysey M, et al. Efficacy and safety of LDL-lowering therapy among men and women:meta-analysis of individual data from 174,000 participants in 27 randomised trials[J]. Lancet,2015,385(9976):1397-1405.
[3] Guyton JR, Bays HE, Grundy SM, et al. An assessment by the statin intolerance panel:2014 update[J]. J Clin Lipidol,2014,8(3 Suppl):S72-S81.
[4] Ambegaonkar BM, Tipping D, Polis AB, et al. Achieving goal lipid levels with ezetimibe plus statin add-on or switch therapy compared with doubling the statin dose:a pooled analysis[J]. Atherosclerosis,2014,237(2):829-837.
[5] Katsiki N, Rizzo M, Mikhailidis DP, et al. New-onset diabetes and statins:throw the bath water out, but, please, keep the baby![J]. Metabolism,2015,64(4):471-475.
[6] Ip CK, Jin DM, Gao JJ, et al. Effects of add-on lipid-modifying therapy on top of background statin treatment on major cardiovascular events:a meta-analysis of randomized controlled trials[J]. Int J Cardiol,2015,191:138-148.
[7] Abifadel M, Varret M, Rabes JP, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia[J]. Nat Genet,2003,34(2):154-156.
[8] Zhang XL, Zhu QQ, Zhu L, et al. Safety and efficacy of anti-PCSK9 antibodies:a meta-analysis of 25 randomized, controlled trials[J]. BMC Med,2015,13:123.
[9] Swergold G, Biedermann S, Renard R, et al. REGN727/SAR236553, a fully-human monoclonal antibody to proprotein convertase subtilisin kexin 9(PCSK9), decreases ApoB and Non-HDL-C when administered intravenously to healthy volunteers[J]. J Clin Lipidol,2011,5(3):219.
[10] Swergold G, Biedermann S, Renard R, et al. REGN727/SAR236553, a fully human proprotein convertase subtilisin kexin 9(PCSK9)monoclonal antibody: effects on safety and lipid and lipoprotein profiles when administered subcutaneously[J]. J Am Coll Cardiol,2011,57(14):2023.
[11] Roth EM, Diller P. Alirocumab for hyperlipidemia:physiology of PCSK9 inhibition, pharmacodynamics and phase Ⅰ and Ⅱ clinical trial results of a PCSK9 monoclonal antibody[J]. Future Cardiol,2014,10(2):183-199.
[12] McKenney JM, Koren MJ, Kereiakes DJ, et al. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy[J]. J Am Coll Cardiol,2012,59(25):2344-2353.
[13] Stein EA, Gipe D, bergeron J, et al. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy:a phase 2 randomised controlled trial[J]. Lancet,2012,380(9836):29-36.
[14] Roth EM, McKenney JM, Hanotin C, et al. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia[J]. N Engl J Med,2012,367(20):1891-1900.
[15] Schwartz GG, Bessac L, Berdan LG, et al. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes:rationale and design of the ODYSSEY outcomes trial[J]. Am Heart J,2014,168(5):682-689.
[16] Kastelein JJ, Ginsberg HN, Langslet G, et al. ODYSSEY FHⅠ and FH Ⅱ:78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia[J]. Eur Heart J,2015,36(43):2996-3003.
[17] Robinson JG, Colhoun HM, Bays HE, et al. Efficacy and safety of alirocumab as add-on therapy in high-cardiovascular-risk patients with hypercholesterolemia not adequately controlled with atorvastatin(20 or 40 mg)or rosuvastatin(10 or 20 mg):design and rationale of the ODYSSEY OPTIONS studies[J]. Clin Cardiol,2014,37(10):597-604.
[18] Kereiakes DJ, Robinson JG, Cannon CP, et al. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy:The ODYSSEY COMBO I study[J]. Am Heart J,2015,169(6):906-915,e913.
[19] Cannon CP, Cariou B, Blom D, et al. Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins:the ODYSSEY COMBO Ⅱ randomized controlled trial[J]. Eur Heart J,2015,36(19):1186-1194.
[20] Colhoun HM, Robinson JG, Farnier M, et al. Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins:rationale and design of the ODYSSEY COMBO Ⅰ and Ⅱ trials[J]. BMC Cardiovasc Disord,2014,14:121.
[21] Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events[J]. N Engl J Med,2015,372(16):1489-1499.
[22] Roth EM, McKenney JM. ODYSSEY MONO:effect of alirocumab 75 mg subcutaneously every 2 weeks as monotherapy versus ezetimibe over 24 weeks[J]. Future Cardiol,2015,11(1):27-37.
[23] Moriarty PM, Jacobson TA, Bruckert E, et al. Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients:design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial[J]. J Clin Lipidol,2014,8(6):554-561.
[24] Stroes EG, Guyton J, Farnier M, et al. Efficacy and safety of different dosing regimens of alirocumab(starting doses of 75 mg every two weeks and 150 mg every four weeks)versus placebo in patients with hypercholesterolemia not treated using statins:the ODYSSEY CHOICEⅡ study[J]. J Am Coll Cardiol,2015,65(10):A1370.

备注/Memo

备注/Memo:
作者简介:苏婷(1988—),硕士,主要从事心血管疾病研究。Email:suting1216@126.com
通信作者:王志禄(1962—),主任医师,教授,主要从事冠心病及动脉硬化研究。Email:Wangzhilu@medmail.com.cn
更新日期/Last Update: 2016-02-20